{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:53:31Z","timestamp":1792068811678,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is the most common cause of dementia and a growing healthcare challenge. Amyloid-targeting therapies (ATT) may slow progression, but implementation is limited by logistical and economic barriers. As primary care is the first contact for most patients with cognitive concerns, quantifying treatment eligibility in this setting is essential. The purpose of this study was to estimate the proportion of primary care patients presenting with cognitive symptoms who are eligible for ATT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cohort study included patients presenting with cognitive symptoms in primary care across the region Sk\u00e5ne, in southern Sweden, recruited between January 2020 and April 2025. Stepwise exclusion criteria based on clinical diagnosis, comorbidities, and treatment contraindications were applied, in alignment with appropriate use recommendations for lecanemab and donanemab, respectively. Eligibility was further refined using CSF biomarkers (A\u03b242\/40 ratio), cognitive performance, and MRI findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a full diagnostic work-up of 607 patients with sequential exclusions, 86 patients (14.2%) and 78 patients (12.8%) ultimately met the eligibility criteria for lecanemab and donanemab, respectively. Due to comorbidities, medication use, and age\/BMI, around 1\/3 of the original population was excluded. Most ineligible patients met more than one exclusion criterion. The eligible population was 63% female, mean age 77 years. Around 65% of the individuals had mild cognitive impairment (MCI), and 35% mild dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>About 13-14% of primary care patients evaluated for cognitive complaints were eligible for ATT. Compared with clinical trials, the eligible population was older and consisted of more women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>BioFINDERPrimary Care study (NCT06120361, Registration date 2 November 2023 https\/\/biofinder.se).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02019-2","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:03:53Z","timestamp":1774087433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms"],"prefix":"10.1186","volume":"18","author":[{"given":"Beata","family":"Borgstr\u00f6m Bolmsj\u00f6","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Barbosa Dj\u00e4rf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Fawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyduine","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2019_CR1","unstructured":"FDA approval LEQEMBI. 2023 https:\/\/web.archive.org\/web\/20230709043242\/https:\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761269Orig1s000TOC.cfm [accessed 13 Oct 2025]."},{"key":"2019_CR2","unstructured":"FDA Donanemab Approval. 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease [accessed 13 Oct 2025]."},{"key":"2019_CR3","unstructured":"Donanemab approval Japan. 2024. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-japan-treatment-early [accessed 23 Oct 2025]."},{"key":"2019_CR4","unstructured":"Donanemab approved in China. 2024. https:\/\/investor.lilly.com\/node\/51751\/pdf [accessed 23 Oct 2025]."},{"key":"2019_CR5","unstructured":"LEQEMBI Approval China. (2024). https:\/\/investors.biogen.com\/news-releases\/news-release-details\/leqembir-lecanemab-approved-treatment-alzheimers-disease-china [accessed 23 Oct 2025]."},{"key":"2019_CR6","unstructured":"LEQEMBI approval Japan. (2023) https:\/\/www.eisai.com\/news\/2023\/news202359.html [accessed 23 Oct 2025]."},{"key":"2019_CR7","unstructured":"Lecanemab EMA. approval. (2024) https:\/\/www.ema.europa.eu\/en\/news\/leqembi-recommended-treatment-early-alzheimers-disease [accessed 13 Oct 2025]."},{"key":"2019_CR8","unstructured":"Donanemab EMA, Approval. (2025). https:\/\/www.alzint.org\/news-events\/news\/ema-recommends-marketing-authorization-for-donanemab-kisunla\/ [accessed 13 Oct 2025]."},{"issue":"7","key":"2019_CR9","doi-asserted-by":"publisher","first-page":"e209218","DOI":"10.1212\/WNL.0000000000209218","volume":"102","author":"HV Nguyen","year":"2024","unstructured":"Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102(7):e209218.","journal-title":"Neurology"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Wimo A, Handels R, Johansson G, Boada M, Engelborghs S, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29:100657.","journal-title":"Lancet Reg Health Eur"},{"key":"2019_CR11","unstructured":"Regionernas samverkansmodell f\u00f6r l\u00e4kemedel. https:\/\/samverkanlakemedel.se\/produktinfo\/leqembi-lekanemab [accessed 23 Oct 2025]."},{"issue":"6","key":"2019_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"4","key":"2019_CR13","doi-asserted-by":"publisher","first-page":"e237230","DOI":"10.1001\/jamanetworkopen.2023.7230","volume":"6","author":"DA Berry","year":"2023","unstructured":"Berry DA, Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, et al. Lecanemab for patients with early Alzheimer disease: bayesian analysis of a phase 2b dose-finding randomized clinical trial. JAMA Netw Open. 2023;6(4):e237230.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2019_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2019_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12888-022-03730-8","volume":"22","author":"L Karimi","year":"2022","unstructured":"Karimi L, Mahboub-Ahari A, Jahangiry L, Sadeghi-Bazargani H, Farahbakhsh M. A systematic review and meta-analysis of studies on screening for mild cognitive impairment in primary healthcare. BMC Psychiatry. 2022;22(1):97.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"2019_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805\u20133.","journal-title":"Epidemiology"},{"issue":"15","key":"2019_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332(15):1245\u201357.","journal-title":"JAMA"},{"issue":"6","key":"2019_CR18","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P, et al. Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. 2025;31(6):2036\u201343.","journal-title":"Nat Med"},{"key":"2019_CR19","unstructured":"BioFINDER study Sweden. The Swedish BioFINDER study https:\/\/biofinder.se\/ [accessed 30 Jan 2026]."},{"issue":"3","key":"2019_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"2019_CR21","doi-asserted-by":"crossref","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150.","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"2019_CR22","unstructured":"HealthCare G. https:\/\/www.readvizamyl.com\/ 2025 [accessed 20 Nov 2025]."},{"issue":"6","key":"2019_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group. Lancet Neurol. 2021;20(6):484\u201396.","journal-title":"Lancet Neurol"},{"key":"2019_CR24","volume-title":"International statistical classification of diseases and related health problems, 10th revision (ICD-10)","author":"World Health Organization","year":"2016","unstructured":"World health organization. International statistical classification of diseases and related health problems, 10th revision (ICD-10). Geneva: World Health Organization; 2016."},{"key":"2019_CR25","volume-title":"Anatomical therapeutic chemical (ATC) classification system","author":"World Health Organization Collaborating Centre for Drug Statistics Methodology","year":"2024","unstructured":"World health organization collaborating centre for drug statistics methodology. Anatomical therapeutic chemical (ATC) classification system. Oslo: Who collaborating centre for drug statistics methodology; 2024."},{"issue":"3","key":"2019_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneurol.2015.10","volume":"11","author":"ND Prins","year":"2015","unstructured":"Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157\u201365.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2019_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338.","journal-title":"Lancet Neurol"},{"issue":"7","key":"2019_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1474-4422(23)00131-X","volume":"22","author":"M Duering","year":"2023","unstructured":"Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023;22(7):602\u201318.","journal-title":"Lancet Neurol"},{"issue":"21","key":"2019_CR29","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/WNL.0b013e3181c34a7d","volume":"73","author":"SM Gregoire","year":"2009","unstructured":"Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, J\u00e4ger HR, et al. The microbleed anatomical rating scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73(21):1759\u201366.","journal-title":"Neurology"},{"issue":"4","key":"2019_CR30","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/alz.13700","volume":"20","author":"EG Klein","year":"2024","unstructured":"Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, et al. How donanemab data address the coverage with evidence development questions. Alzheimers Dement. 2024;20(4):3127\u201340.","journal-title":"Alzheimers Dement"},{"key":"2019_CR31","unstructured":"Phase AD. trial. Biogen. https:\/\/www.leqembihcp.com\/about-leqembi\/study-2-clarity-ad?utm_source 10\/25 [accessed 01 nov 2025]."},{"key":"2019_CR32","unstructured":"Therapeuticgoods administration (TGA). Australia \u2013 Lecanemab product information therapeutic goods administration (TGA), Australia Leqembi (lecanemab) \u2013 product information. Australian government department of health and aged care; 2024. https:\/\/www.tga.gov.au\/news\/news-articles\/tga-approves-registration-lecanemab-leqembi. (accessed 01 February 2026)."},{"issue":"19","key":"2019_CR33","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr., et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. 2023;101(19):e1837\u201349.","journal-title":"Neurology"},{"issue":"1","key":"2019_CR34","doi-asserted-by":"publisher","first-page":"e16534","DOI":"10.1111\/ene.16534","volume":"32","author":"G Logroscino","year":"2025","unstructured":"Logroscino G, Urso D, Gnoni V, Giugno A, Vilella D, Castri A, et al. Mild cognitive impairment and early Alzheimer\u2019s disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab. Eur J Neurol. 2025;32(1):e16534.","journal-title":"Eur J Neurol"},{"issue":"9","key":"2019_CR35","doi-asserted-by":"publisher","first-page":"e209402","DOI":"10.1212\/WNL.0000000000209402","volume":"102","author":"A Dittrich","year":"2024","unstructured":"Dittrich A, Westman E, Shams S, Skillb\u00e4ck T, Zetterberg H, Blennow K, et al. Proportion of community-dwelling individuals older than 70 years eligible for Lecanemab initiation: the gothenburg H70 birth cohort study. Neurology. 2024;102(9):e209402.","journal-title":"Neurology"},{"issue":"3","key":"2019_CR36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3233\/JAD-150796","volume":"50","author":"JJ Claus","year":"2016","unstructured":"Claus JJ, Staekenborg SS, Roorda JJ, Stevens M, Herderschee D, van Maarschalkerweerd W, et al. Low prevalence of mixed dementia in a cohort of 2,000 elderly patients in a memory clinic setting. J Alzheimers Dis. 2016;50(3):797\u2013806.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2019_CR37","doi-asserted-by":"publisher","first-page":"100088","DOI":"10.1016\/j.tjpad.2025.100088","volume":"12","author":"KE Jones","year":"2025","unstructured":"Jones KE, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr., et al. Eligibility for donanemab trial in a population-based study of cognitive aging. J Prev Alzheimers Dis. 2025;12(4):100088.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"2019_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, et al. Lecanemab treatment in a specialty memory clinic. JAMA Neurol. 2025;82(7):655\u201365.","journal-title":"JAMA Neurol"},{"issue":"18","key":"2019_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02019-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02019-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02019-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:37:48Z","timestamp":1781642268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02019-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02019-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was conducted in accordance with the regulatory requirements and the ethical principles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly. The study was approved by the Swedish Ethical Review Authority as The Swedish BioFINDER - Primary Care Study Dnr 2019\u201304320. An informed consent was signed and collected before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NMC- reports a relationship with Biogen Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with BioArctic AB that includes: consulting or advisory and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, a relationship with Novo Nordisk Pharma Co Ltd that includes: consulting or advisory and speaking and lecture fees, a relationship with Merck & Co Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with Owkin Inc that includes: consulting or advisory and speaking and lecture fees. SP- reports a relationship with BioArctic AB that includes: consulting or advisory and speaking and lecture fees, a relationship with Eisai Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, reports a relationship with novo that includes: consulting or advisory and speaking and lecture fees, a relationship with Roche that includes: consulting or advisory and speaking and COI form lecture fees. SP serving as associate editor at JPAD OH reports a relationship with Eli Lilly and Company that includes: employment. RS- reports a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, a relationship with Novo Nordisk Pharma Co Ltd that includes: consulting or advisory and speaking and lecture fees, a relationship with Roche that includes: consulting or advisory and speaking and lecture fees, a relationship with Triolab that includes: consulting or advisory and speaking and lecture fees. SES- reports a relationship with Eisai Inc that includes: board membership, consulting or advisory, and speaking and lecture fees, a relationship with Novo Nordisk Inc that includes: board membership, consulting or advisory, and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: speaking and lecture fees, a relationship with Medscape Education that includes: speaking and lecture fees, a relationship with peer reviwew that includes: speaking and lecture fees. SES is serving as a guest editor of a special issue of A&D:DADM on amyloid-targeted treatments. LC- reports a relationship with Novo Nordisk Inc that includes: equity or stocks, a relationship with Eli Lilly and Company that includes: equity or stocks. Other authors, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}